Even though high NORAD levels are correlated with a lower relapse-free survival in poorly differentiated (grade 3) tumors (n = 417, p = 0.026), no association between NORAD expression and survival for the remaining tumor subtypes (luminal or HER2+) was found (Figures S1C–S1F). This evidence concerns the gene NORAD and neoplasm.